IDUN Pharmaceuticals/Apoptech
Executive Summary
Two biotech start-ups focusing on programmable cell death have merged. The move will "broaden IDUN's technology base," increase research staff and "provide sufficient financing to weather the harsh conditions in the current marketplace," La Jolla, Calif.- based IDUN says. The new company, which just raised $7.2 mil. in venture capital from Accel Partners and Venrock Associates, will retain the IDUN name and be based in La Jolla